2021
Financial toxicity in patients with gynecologic malignancies: a cross sectional study
Zeybek B, Webster E, Pogosian N, Tymon-Rosario J, Balch A, Altwerger G, Clark M, Menderes G, Huang G, Azodi M, Ratner ES, Schwartz PE, Santin AD, Andikyan V. Financial toxicity in patients with gynecologic malignancies: a cross sectional study. Journal Of Gynecologic Oncology 2021, 32: e87. PMID: 34431257, PMCID: PMC8550931, DOI: 10.3802/jgo.2021.32.e87.Peer-Reviewed Original ResearchConceptsCross-sectional studyGynecologic malignanciesFinancial toxicityPatient demographicsSectional studyMalignancy typeGynecologic oncology patientsOvarian cancer patientsPatient/diseaseCost of careFinancial burdenHigh financial burdenTreatment regimenHigh financial toxicityOncology patientsDisease characteristicsGynecologic cancerCancer careCancer patientsRisk factorsClinical trialsCOST scoreMedian COST scorePatientsSignificant burden
2019
Synergistic clinical efficacy of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma
Tymon-Rosario J, Zeybek B, Han C, Santin AD. Synergistic clinical efficacy of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma. Annals Of Translational Medicine 2019, 0: s308. PMID: 32016027, PMCID: PMC6976388, DOI: 10.21037/atm.2019.10.28.Peer-Reviewed Original ResearchPlatinum-based chemotherapyOvarian cancerInitial platinum-based chemotherapyPlatinum-resistant ovarian carcinomaGynecologic cancer deathStandard treatment regimenCancer respondMost patientsTreatment regimenClinical efficacyCancer deathOvarian carcinomaCommon causeDeath rateCancerPrecision medicineChemotherapyPatientsToxic effectsDeathPembrolizumabRegimenCarcinomaTherapyNiraparib